TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Exploratory endpoints assess vascular function and inflammation biomarkers

NCT Number	NCT07487363
Lead Sponsor	Hudson Biotech
Conditions	Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction
Enrollment	80 participants
Start Date	2026-02-05
Primary Completion	2027-02-14 (estimated)
Study Completion	2028-02-17 (estimated)
Updated on ClinicalTrials.gov	2026-03-23